Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. JAGX
stocks logo

JAGX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
4.21M
+19.98%
-4.260
-96.61%
3.67M
+65.76%
-2.040
-87.78%
4.24M
+42.33%
-1.490
-85.48%
Estimates Revision
The market is revising No Change the revenue expectations for Jaguar Health, Inc. (JAGX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -37.85%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-37.85%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Jaguar Health Inc (JAGX.O) is -0.12, compared to its 5-year average forward P/E of -2.16. For a more detailed relative valuation and DCF analysis to assess Jaguar Health Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.16
Current PE
-0.12
Overvalued PE
1.13
Undervalued PE
-5.46

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
2.73
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
16.78
Undervalued EV/EBITDA
-11.31

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.50
Current PS
0.00
Overvalued PS
9.75
Undervalued PS
-2.75
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

JAGX News & Events

Events Timeline

(ET)
2025-12-02
09:20:00
Jaguar Health Seeks EMA Approval for Canalevia in Dogs
select
2025-11-24 (ET)
2025-11-24
09:20:22
Jaguar Health obtains patent for crofelemer to treat short bowel syndrome
select
2025-11-17 (ET)
2025-11-17
08:29:34
Jaguar Health announces Q3 earnings per share of $6.28 compared to a loss of $26.29 in the same period last year.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-25Benzinga
Keysight Shares Rise Approximately 15%; Check Out 20 Stocks Making Moves in Premarket Trading

  • Keysight Technologies Earnings Report: Keysight Technologies Inc. reported fourth-quarter earnings of $1.91 per share and revenue of $1.42 billion, surpassing analyst expectations, leading to a 14.8% increase in share price during pre-market trading.

  • Other Notable Gainers: Several stocks saw significant pre-market gains, including Icon Energy Corp (+33.4%), WeShop Holdings Limited (+23.1%), and Inno Holdings Inc (+23%), following positive trading sessions.

  • Stocks Experiencing Losses: MingZhu Logistics Holdings Ltd led the decliners with a 15.8% drop, alongside other companies like Prestige Wealth Inc (-11.2%) and Pasithea Therapeutics Corp (-11.1%) after previous gains.

  • Market Overview: The article provides a snapshot of various stocks' performances in pre-market trading, highlighting both gainers and losers, along with specific financial results that influenced these movements.

[object Object]
Preview
9.0
11-24Newsfilter
Jaguar Health Submits Amended Protocol for Crofelemer Clinical Trial in MVID Patients
  • Clinical Trial Progress: Jaguar Health has submitted an amended protocol to expedite the approval of Crofelemer for microvillus inclusion disease (MVID) patients. The drug has the potential to reduce daily parenteral support needs by up to 37%, significantly improving patients' quality of life.
  • FDA Meeting Feedback: The company met with the FDA on October 2, 2025, to discuss the progress of Crofelemer's clinical trial. Based on FDA feedback, Jaguar expects the amended protocol to support a faster review and approval process.
  • International Collaboration: Jaguar has also engaged with the European Medicines Agency (EMA) regarding the potential approval of Crofelemer based on studies involving a small number of MVID patients. This indicates the drug's significant potential in treating extremely rare pediatric disorders.
  • Initial Results Showcase: Initial results from an independent trial in the UAE show that Crofelemer can reduce parenteral support needs in MVID patients by 12% to 37%. This finding provides strong support for further evaluation of Crofelemer in MVID patients.
[object Object]
Preview
5.0
10-25Yahoo Finance
Jaguar Health Unveils New Employee Incentive Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)

  • RSU Grants: Jaguar Health, Inc. granted a total of 1,500 restricted stock units (RSUs) to three new employees, with vesting over one year contingent on their continued service.

  • Company Overview: Jaguar Health focuses on developing plant-derived prescription medicines for gastrointestinal issues in humans and animals, with its subsidiary Napo Pharmaceuticals offering FDA-approved treatments for noninfectious diarrhea.

  • International Expansion: Jaguar established Napo Therapeutics in Italy to enhance access to its products in Europe, particularly for orphan diseases.

  • Forward-Looking Statements: The company issued forward-looking statements regarding its future expectations, emphasizing that these predictions are subject to various risks and uncertainties.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Jaguar Health Inc (JAGX) stock price today?

The current price of JAGX is 1.1 USD — it has increased 7.84 % in the last trading day.

arrow icon

What is Jaguar Health Inc (JAGX)'s business?

Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.

arrow icon

What is the price predicton of JAGX Stock?

Wall Street analysts forecast JAGX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for JAGX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Jaguar Health Inc (JAGX)'s revenue for the last quarter?

Jaguar Health Inc revenue for the last quarter amounts to 3.08M USD, decreased -0.80 % YoY.

arrow icon

What is Jaguar Health Inc (JAGX)'s earnings per share (EPS) for the last quarter?

Jaguar Health Inc. EPS for the last quarter amounts to -6.28 USD, decreased -76.11 % YoY.

arrow icon

What changes have occurred in the market's expectations for Jaguar Health Inc (JAGX)'s fundamentals?

The market is revising No Change the revenue expectations for Jaguar Health, Inc. (JAGX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -37.85%.
arrow icon

How many employees does Jaguar Health Inc (JAGX). have?

Jaguar Health Inc (JAGX) has 49 emplpoyees as of December 05 2025.

arrow icon

What is Jaguar Health Inc (JAGX) market cap?

Today JAGX has the market capitalization of 4.07M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free